Cross-Sector entity
Of the tracked stories, 3 of 5 also mention Delhi High Court, the most common co-covered peer. That works out to roughly 0.3 stories per week across a 104-day span. The busiest single day carried 3. Coverage clusters in regulation, which accounts for 3 of those 5, with the remainder spread across 2 other categories.
5 verified stories tracked
Last mentioned: Mar 18, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 20 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 3 of 5 also mention Delhi High Court, the most common co-covered peer. That works out to roughly 0.3 stories per week across a 104-day span. The busiest single day carried 3. Coverage clusters in regulation, which accounts for 3 of those 5, with the remainder spread across 2 other categories. We currently track 5 Cross-Sector stories that mention Central Drugs Standard Control Organisation (CDSCO), published between March 15, 2026 and June 26, 2026. 60% of these stories carry negative sentiment. The tracked stories average 2.4 original sources each.
Computed from the 5 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Central Drugs Standard Control Organisation (CDSCO). Shared-story counts are live from our verified record — not editorial picks.
Target Milestone
Goal to reach $50 billion market size and 10-12% global market share.
Expected Response
Deadline for CDSCO to justify the delay in regulatory action (Estimated).
Contempt Petition Filed
Petitioners allege CDSCO failed to act on the court's previous safety mandate.
Notice Issued
Justice Sachin Datta issues formal contempt notice seeking a response from the CDSCO.
Rollout of Production Linked Incentive schemes for high-end medical equipment.
Chintan Shivir
Department of Commerce holds strategic brainstorming to boost exports.
Original Court Order
Delhi HC directs CDSCO to examine safety and regulatory concerns of diabetes drugs used for weight management.
Contempt Petition Filed
Petitioners move court alleging CDSCO failed to meet the review deadline.
Initial Judicial Order
Delhi HC directs CDSCO to examine the safety of diabetes drugs used for weight management.
Initial Court Order
Delhi HC directs CDSCO to evaluate safety of diabetes drugs for weight loss.
Policy Launch
National Medical Device Policy 2023 is officially notified.
Eli Lilly's RET inhibitor Tanstrive hits the Indian market at Rs 2.15 lakh per 14-day course, promising targeted therapy for advanced solid tumors but raising urgent questions about affordability, insurance coverage, and diagnostic capacity in the country's strained healthcare system.
Source: Business News India · Mint
The Delhi High Court has initiated contempt proceedings against India's top drug regulator, the CDSCO, for failing to examine safety concerns regarding the off-label use of diabetes medications for weight loss. This judicial escalation highlights growing concerns over the unregulated boom of GLP-1 agonists in the Indian market.
The Delhi High Court has issued a contempt notice to India's drug regulator, CDSCO, for failing to comply with judicial orders to evaluate the safety of diabetes drugs used off-label for weight loss. This escalation signals a growing legal intolerance for regulatory delays amidst a global surge in GLP-1 receptor agonist demand.
The Delhi High Court has initiated contempt proceedings against India's top drug regulator, the CDSCO, for failing to act on a judicial mandate to evaluate the safety of diabetes medications used off-label for weight loss. This escalation highlights growing judicial impatience with regulatory inertia regarding the global surge in GLP-1 receptor agonist use.
Source: Yes Punjab News · prokerala.com
The Indian Department of Commerce has convened a 'Chintan Shivir' to overhaul the nation's medical device export framework. This strategic brainstorming session aims to address regulatory hurdles and incentivize domestic manufacturing to position India as a global med-tech hub.
Source: oklahomacitysun.com · russiaherald.com
